TOP TEN perturbations for 38909_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38909_at
Selected probe(set): 205676_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38909_at (205676_at) across 6674 perturbations tested by GENEVESTIGATOR:
VTX-2337 study 1 / untreated monocyte sample
Relative Expression (log2-ratio):5.629366Number of Samples:3 / 3
| Experimental | VTX-2337 study 1 |
| Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
| Control | untreated monocyte sample |
| Peripheral blood monocytes isolated from healthy donors. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):5.149743Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):5.0293245Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-4.8204327Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-4.6263533Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.4986076Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):4.4853888Number of Samples:2 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Relative Expression (log2-ratio):4.459175Number of Samples:2 / 5
| Experimental | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):-4.43715Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):4.3797617Number of Samples:2 / 7
| Experimental | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. | |
| Control | expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary. |